HUP0100801A2 - Metformin és fibrát kombinációját tartalmazó gyógyászati készítmények és ezek alkalmazása kórosan magas vércukorszint csökkentését célzó gyógyszerek előállítására - Google Patents

Metformin és fibrát kombinációját tartalmazó gyógyászati készítmények és ezek alkalmazása kórosan magas vércukorszint csökkentését célzó gyógyszerek előállítására

Info

Publication number
HUP0100801A2
HUP0100801A2 HU0100801A HUP0100801A HUP0100801A2 HU P0100801 A2 HUP0100801 A2 HU P0100801A2 HU 0100801 A HU0100801 A HU 0100801A HU P0100801 A HUP0100801 A HU P0100801A HU P0100801 A2 HUP0100801 A2 HU P0100801A2
Authority
HU
Hungary
Prior art keywords
fibrate
combination
metformin
preparation
intented
Prior art date
Application number
HU0100801A
Other languages
English (en)
Inventor
Yves Bonhomme
Philippe Briet
Original Assignee
Merck Patent Gmbh.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh. filed Critical Merck Patent Gmbh.
Publication of HUP0100801A2 publication Critical patent/HUP0100801A2/hu
Publication of HUP0100801A3 publication Critical patent/HUP0100801A3/hu
Publication of HU224619B1 publication Critical patent/HU224619B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A találmány tárgya gyógyászati készítmény, amely hatóanyagkéntmetformint - adott esetben gyógyászati szempontból elfogadható sójaalakjában - és egy fibrátot, nevezetesen fenofibrátot vagybezafibrátot tartalmaz egy vagy több, gyógyászati szempontbólelfogadható segédanyaggal alkotott kombinációban. A találmány szerintikészítmények különösen alkalmasak nem inzulinfüggő cukorbetegség(NIDD) kezelésére. Ó
HU0100801A 1998-02-12 1999-01-30 Metformin és fibrát kombinációját tartalmazó gyógyászati készítmények és ezek alkalmazása kórosan magas vércukorszint csökkentését célzó gyógyszerek előállítására HU224619B1 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9801709A FR2774591B1 (fr) 1998-02-12 1998-02-12 Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie
PCT/EP1999/000614 WO1999040904A2 (en) 1998-02-12 1999-01-30 Pharmaceutical composition comprising a combination of metformin and fibrate, and its use for the treatment of hyperglycemia

Publications (3)

Publication Number Publication Date
HUP0100801A2 true HUP0100801A2 (hu) 2001-08-28
HUP0100801A3 HUP0100801A3 (en) 2001-12-28
HU224619B1 HU224619B1 (hu) 2005-11-28

Family

ID=9522912

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0100801A HU224619B1 (hu) 1998-02-12 1999-01-30 Metformin és fibrát kombinációját tartalmazó gyógyászati készítmények és ezek alkalmazása kórosan magas vércukorszint csökkentését célzó gyógyszerek előállítására

Country Status (28)

Country Link
US (1) US6372790B1 (hu)
EP (1) EP1054665B1 (hu)
JP (1) JP4767411B2 (hu)
KR (1) KR100567608B1 (hu)
CN (1) CN1151785C (hu)
AR (1) AR018286A1 (hu)
AT (1) ATE204754T1 (hu)
AU (1) AU746821B2 (hu)
BR (1) BRPI9907866B8 (hu)
CA (1) CA2320039C (hu)
CZ (1) CZ290101B6 (hu)
DE (1) DE69900249T2 (hu)
DK (1) DK1054665T3 (hu)
ES (1) ES2162517T3 (hu)
FR (1) FR2774591B1 (hu)
HK (1) HK1034913A1 (hu)
HU (1) HU224619B1 (hu)
ID (1) ID26254A (hu)
MY (1) MY118164A (hu)
NO (1) NO328314B1 (hu)
PL (1) PL196874B1 (hu)
PT (1) PT1054665E (hu)
RU (1) RU2207850C2 (hu)
SK (1) SK283212B6 (hu)
TW (1) TW518222B (hu)
UA (1) UA70315C2 (hu)
WO (1) WO1999040904A2 (hu)
ZA (1) ZA991077B (hu)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4278863B2 (ja) * 1997-12-08 2009-06-17 ブリストル−マイヤーズ スクイブ カンパニー メトホルミンの新規塩および方法
US6982281B1 (en) 2000-11-17 2006-01-03 Lipocine Inc Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
FR2796551B1 (fr) * 1999-07-23 2003-07-25 Lipha Nouveaux sels de metformine, leur procede d'obtention et les compositions pharmaceutiques en renfermant
FR2796940B1 (fr) * 1999-07-26 2005-04-08 Lipha Nouveaux sels de metformine, leur procede d'obtention et les compositions pharmaceutiques en renfermant
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
JP4879433B2 (ja) * 2000-01-13 2012-02-22 エミスフェアー・テクノロジーズ・インク 活性剤を送達するための化合物および組成物
US6531158B1 (en) * 2000-08-09 2003-03-11 Impax Laboratories, Inc. Drug delivery system for enhanced bioavailability of hydrophobic active ingredients
JP4829411B2 (ja) * 2001-02-23 2011-12-07 キッセイ薬品工業株式会社 Ｃ型慢性肝炎治療剤
GB0119480D0 (en) 2001-08-09 2001-10-03 Jagotec Ag Novel compositions
AU2002356419A1 (en) 2002-06-17 2003-12-31 Themis Laboratories Private Limited Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them
EP1424070A1 (en) * 2002-11-28 2004-06-02 Fournier Laboratories Ireland Limited Combination of a PPAR alpha agonist and metformin for decreasing the serum triglycerides
JP2006511525A (ja) 2002-12-13 2006-04-06 ヤゴテック アーゲー ナノ粒子状スピロノラクトン局所製剤
FR2851734B1 (fr) * 2003-02-28 2006-06-09 Galenix Innovations Procede pour la fabrication d'une composition pharmaceutique sous la forme de comprimes contenant un fibrate et comprimes obtenus selon le procede
FR2858556B1 (fr) * 2003-08-06 2006-03-10 Galenix Innovations Composition pharmaceutique solide dispersible et/ou orodispersible non pelliculee contenant au moins le principe actif metformine, et procede de preparation
US8062664B2 (en) * 2003-11-12 2011-11-22 Abbott Laboratories Process for preparing formulations of lipid-regulating drugs
KR101329369B1 (ko) 2003-12-19 2013-11-14 오메가 바이오 파마(아이.피.3) 리미티드 당뇨 치료용 조성물 및 방법
EP1559419A1 (en) * 2004-01-23 2005-08-03 Fournier Laboratories Ireland Limited Pharmaceutical formulations comprising metformin and a fibrate, and processes for their obtention
CA2555316A1 (en) * 2004-02-09 2005-08-18 Aska Pharmaceutical Co., Ltd. Combined pharmaceutical composition
EP1591114A1 (en) * 2004-03-12 2005-11-02 Fournier Laboratories Ireland Limited Use of metformin and orlistat for the treatment or prevention of obesity
US20060286182A1 (en) * 2005-06-21 2006-12-21 Abeille Pharmaceuticals, Inc. Synergistic cinnamon combinations and methods for enhancing insulin activity
GB0602639D0 (en) * 2006-02-09 2006-03-22 Novartis Ag Organic compounds
BRPI0621942A2 (pt) 2006-08-04 2011-10-18 Aska Pharm Co Ltd preparação que reduz uma concentração de um ácido graxo livre e/ou fibrinogênio no sangue, agente para redução da quantidade de um ácido graxo livre no sangue, agente para redução da quantidade de fibrinogênio no sangue, método de prevenção ou tratamento de hiper-acidemia de ácido graxo livre, sìndrome metabólica, diabetes tipo ii, complicações causadas por diabetes tipo ii, lipotoxicidade, metabolismo anormal de lipìdeos, intoleráncia à glicose, secreção prejudicada de insulina, gordura hepática, lipoproteinemia de hipo-alta densidade, ou trombose, e uso de uma preparação
CN101342164B (zh) * 2007-08-21 2011-04-20 阜新市仙鹤制药有限责任公司 苯扎贝特控释制剂及其制备方法
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
ES2344183B1 (es) * 2009-02-18 2011-06-10 Italfarmaco, S.A. Uso de agentes sensibilizantes a insulina por via vaginal.
US9339458B2 (en) * 2009-02-18 2016-05-17 Itf Research Pharma, S.L.U. Use of vaginal insulin sensitizing agents
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
JP2012171911A (ja) 2011-02-22 2012-09-10 Kao Corp Ｐｐａｒ活性化剤
US8765811B2 (en) * 2012-07-10 2014-07-01 Thetis Pharmaceuticals Llc Tri-salt form of metformin
CN104684889A (zh) * 2012-07-10 2015-06-03 西蒂斯制药有限责任公司 二甲双胍的三盐形式
US9382187B2 (en) * 2012-07-10 2016-07-05 Thetis Pharmaceuticals Llc Tri-salt form of metformin
EP3140316A1 (en) 2014-05-05 2017-03-15 Thetis Pharmaceuticals LLC Compositions and methods relating to ionic salts of peptides
WO2015183794A1 (en) 2014-05-27 2015-12-03 City Of Hope Tgr5 agonist complexes for treating diabetes and cancer
CN107074884A (zh) 2014-06-18 2017-08-18 西蒂斯制药有限责任公司 活性剂的矿物质氨基酸复合物
US9242008B2 (en) 2014-06-18 2016-01-26 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of fatty acids
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
FR3050112B1 (fr) * 2016-04-15 2020-09-04 Soc Civ Immobiliere Gecinq Utilisation de l'acide fenofibrique dans le traitement des maladies hepatiques
JP6906047B2 (ja) 2016-06-03 2021-07-21 テティス・ファーマシューティカルズ・エルエルシー 特異的炎症収束性メディエーターの塩に関連する組成物及び方法
US10344002B2 (en) 2016-09-26 2019-07-09 Nusirt Sciences, Inc. Compositions and methods for treating metabolic disorders
FR3056908B1 (fr) * 2016-09-30 2019-04-19 Nashpharm Sel de metformine et d'elafibranor presentant une activite duale pour le traitement de l'obesite associee a la steato-hepatite non alcoolique (nash) et a l'hypertriglyceridemie
WO2018098501A1 (en) 2016-11-28 2018-05-31 Lipocine Inc. Oral testosterone undecanoate therapy
GB2599950A (en) * 2020-10-16 2022-04-20 Zentiva Ks Pharmaceutical compositions with low amounts of nitrosamine impurities and methods for producing the same
WO2023119100A1 (en) * 2021-12-22 2023-06-29 Mankind Pharma Ltd. Stable pharmaceutical compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2264525B1 (hu) * 1974-03-22 1977-11-04 Expl Marques Brevets Et
US4080472A (en) 1974-03-22 1978-03-21 Societe D'etudes Et D'exploitation De Marques Et Brevets S.E.M.S. Metformin 2-(p-chlorophenoxy)-2-methylpropionate
DE3729209A1 (de) * 1987-09-01 1989-03-09 Boehringer Mannheim Gmbh Verwendung von bezafibrat zur behandlung von diabetes
JP3852621B2 (ja) * 1992-01-21 2006-12-06 あすか製薬株式会社 血管内皮細胞機能改善剤
WO1998005331A2 (en) * 1996-08-02 1998-02-12 Ligand Pharmaceuticals Incorporated Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators

Also Published As

Publication number Publication date
KR100567608B1 (ko) 2006-04-04
SK283212B6 (sk) 2003-03-04
HK1034913A1 (en) 2001-11-09
DK1054665T3 (da) 2001-12-27
CZ290101B6 (cs) 2002-05-15
KR20010040925A (ko) 2001-05-15
BRPI9907866B1 (pt) 2017-08-15
ATE204754T1 (de) 2001-09-15
US6372790B1 (en) 2002-04-16
JP2002502869A (ja) 2002-01-29
ZA991077B (en) 1999-08-11
AU746821B2 (en) 2002-05-02
HUP0100801A3 (en) 2001-12-28
HU224619B1 (hu) 2005-11-28
EP1054665A2 (en) 2000-11-29
FR2774591A1 (fr) 1999-08-13
FR2774591B1 (fr) 2000-05-05
CA2320039A1 (en) 1999-08-19
UA70315C2 (en) 2004-10-15
WO1999040904A3 (en) 1999-09-30
PL342665A1 (en) 2001-07-02
PT1054665E (pt) 2002-02-28
JP4767411B2 (ja) 2011-09-07
NO328314B1 (no) 2010-01-25
CN1151785C (zh) 2004-06-02
CN1290160A (zh) 2001-04-04
BRPI9907866B8 (pt) 2021-05-25
SK11562000A3 (sk) 2000-12-11
MY118164A (en) 2004-09-30
ID26254A (id) 2000-12-07
EP1054665B1 (en) 2001-08-29
RU2207850C2 (ru) 2003-07-10
DE69900249T2 (de) 2002-06-13
WO1999040904A2 (en) 1999-08-19
BR9907866A (pt) 2000-10-31
TW518222B (en) 2003-01-21
PL196874B1 (pl) 2008-02-29
CZ20002828A3 (cs) 2000-11-15
NO20004056D0 (no) 2000-08-11
ES2162517T3 (es) 2001-12-16
DE69900249D1 (de) 2001-10-04
AR018286A1 (es) 2001-11-14
NO20004056L (no) 2000-08-11
AU2923399A (en) 1999-08-30
CA2320039C (en) 2008-07-22

Similar Documents

Publication Publication Date Title
HUP0100801A2 (hu) Metformin és fibrát kombinációját tartalmazó gyógyászati készítmények és ezek alkalmazása kórosan magas vércukorszint csökkentését célzó gyógyszerek előállítására
CA2408142A1 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
DE60236541D1 (de) Inhibitoren von 11-beta-hydroxysteroiddehydrogenase typ 1
HUP0203330A2 (hu) Benzamidszármazékot tartalmazó javított oldhatóságú és orális felszívódású gyógyszerkészítmények
HRP20020088B1 (en) Levodopa/carbidopa/entacapone pharmaceutical preparation
MXPA04004837A (es) Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
MXPA04004842A (es) Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1.
HUP0400932A2 (hu) Nateglinidet és más antidiabetikus vegyületet tartalmazó gyógyszerkészítmény, eljárás az előállítására és az alkalmazására
MY141243A (en) Pharmaceutical compositions comprising metformine and glibenclamide for the treatment of type-ii diabetes mellitus
HUP0301121A2 (hu) Külsżleges gyógyszerkészítmények és gyógykezelések
EA200200812A1 (ru) Фармацевтическая композиция, содержащая низкую дозу энтекавира, и ее применение
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
RS50768B (sr) Režim doziranja i farmaceutska formulacija za urgentnu zaštitu
ATE243196T1 (de) Piperidine und pyrrolidine
DE50203456D1 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
AU2002214389A1 (en) Pharmaceutical composition containing honey for the treatment of wounds
RS44204A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
DK1303278T3 (da) Kombination af et transdermalt terapeutisk system og et oralt og/eller parenteralt præparat indeholdende dopaminagonister til behandling af dopaminerge sygdomme
RS50298B (sr) Direktno kompresibilna matrica za kontrolisano oslobađanje pojedinačnih dnevnih doza klaritromicina
CO5160272A1 (es) Combinacion de cerivastatina y fibratos
NZ508371A (en) Therapeutic anti-cold agent containing isomalt as an active ingredient
HUP0103819A3 (en) Crystalline efavirenz pharmaceutical compositions containing it as active ingredient, and use of efavirenz for making medicament available for inhibitions of reverse transcriptase and for treating hiv infection
CA2504872A1 (en) Use of resveratrol for the preparation of a medicament useful for the treatment of influenza virus infections
RS44304A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
MXPA04005033A (es) Composicion farmaceutica que comprende una combinacion de metformina y acido 4-oxobutanoico y el uso de la misma para el tratamiento contra diabetes.

Legal Events

Date Code Title Description
HFG4 Patent granted, date of granting

Effective date: 20051013